[Hereditary breast carcinomas pathologist's perspective].

Abstract excerpt

Breast cancers occurring in the context of a hereditary mutation of a predisposition gene represent 5 to 10% of all breast cancers, 20 to 25% of which being due to a mutation in the BRCA1 or BRCA2 genes. Authorization to market PARP inhibitors for breast cancer patients with hereditary BRCA1 and 2 mutations has recently been obtained. Given the annual frequency of breast cancer, morphological identification could...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Artificial Intelligence
• Share to Carcinoma, Lobular
• Share to Genes, erbB-2